BIOMAT Database Logo BIOMAT Database Logo

The treatment of neuroblastoma with 131I-MIBG. 1987

R Mastrangelo

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007462 Iodobenzenes Any derivative of BENZENE that contains IODINE.
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D019797 3-Iodobenzylguanidine A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase. (3-Iodo-(131I)benzyl)guanidine,Iobenguane,MIBG,3-Iodobenzylguanidine, 123I Labeled,3-Iodobenzylguanidine, 125I Labeled,Iobenguane (131I),m-Iodobenzylguanidine,meta-Iodobenzylguanidine,123I Labeled 3-Iodobenzylguanidine,125I Labeled 3-Iodobenzylguanidine,3 Iodobenzylguanidine,3 Iodobenzylguanidine, 123I Labeled,3 Iodobenzylguanidine, 125I Labeled,m Iodobenzylguanidine,meta Iodobenzylguanidine

Related Publications

R Mastrangelo
[131I-MIBG-meta-iodobencylguanidine (131I-MIBG) in the study of neuroblastoma].
March 1987, Anales espanoles de pediatria,
R Mastrangelo
[131I-MIBG scintigraphy of neuroblastoma].
April 1988, Rinsho hoshasen. Clinical radiography,
R Mastrangelo
Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives.
January 1987, Medical and pediatric oncology,
R Mastrangelo
[Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].
January 2006, Nuklearmedizin. Nuclear medicine,
R Mastrangelo
The role of 131I-MIBG in high-risk neuroblastoma treatment.
January 2009, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses,
R Mastrangelo
[Experience with 131I-MIBG scintigraphy of children with neuroblastoma].
January 1987, Radiobiologia, radiotherapia,
R Mastrangelo
The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription.
September 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
R Mastrangelo
Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
April 2020, Nuclear medicine communications,
R Mastrangelo
[131I]MIBG as a first line treatment in advanced neuroblastoma.
December 1995, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR),
R Mastrangelo
Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
October 1996, Physics in medicine and biology,
Copied contents to your clipboard!